A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Inclusion Criteria: * Adult patients, \>/=18 years of age * Diagnosis of diabetes mellitus, type 2 * Patients treated with stable sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy for at least 12 weeks prior to screening * HbA1c \>/=7% and \</=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit * Fasting plasma glucose \</=240 mg/dL at pre-randomization visit * Agreement to maintain diet and exercise habits during the study Exclusion Criteria: * Patients with Type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months * Any previous treatment with thiazolidinedione or a dual PPAR agonist * Any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin) * Any anti-hyperglycemic medication other than sulfonylurea alone or in combination with metformin within 12 weeks prior to screening * Symptomatic congestive heart failure classified as New York Heart Association class II-IV at screening